ACCESS REALMONEY
Email This Article
Headlines & Perspectives
Biogen, Genentech's Rituxan Fails New Study
By
Adam Feuerstein
04/29/08 - 10:12 AM EDT
The drug failed to benefit patients with lupus, according to new late-stage study data.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
Sign up for our FREE newsletters now.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
